Editas Medicine (EDIT) Competitors $1.62 -0.03 (-1.82%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$1.58 -0.04 (-2.47%) As of 05:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT vs. KURA, ZYBT, URGN, STOK, VERV, UPB, MNMD, GHRS, SAGE, and RGNXShould you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Kura Oncology (KURA), Zhengye Biotechnology (ZYBT), UroGen Pharma (URGN), Stoke Therapeutics (STOK), Verve Therapeutics (VERV), Upstream Bio (UPB), Mind Medicine (MindMed) (MNMD), GH Research (GHRS), Sage Therapeutics (SAGE), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry. Editas Medicine vs. Kura Oncology Zhengye Biotechnology UroGen Pharma Stoke Therapeutics Verve Therapeutics Upstream Bio Mind Medicine (MindMed) GH Research Sage Therapeutics REGENXBIO Editas Medicine (NASDAQ:EDIT) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends. Do institutionals and insiders believe in EDIT or KURA? 71.9% of Editas Medicine shares are held by institutional investors. 1.9% of Editas Medicine shares are held by insiders. Comparatively, 6.4% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, EDIT or KURA? Kura Oncology has higher revenue and earnings than Editas Medicine. Kura Oncology is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEditas Medicine$32.31M4.20-$153.22M-$2.88-0.56Kura Oncology$53.88M9.73-$152.63M-$2.03-3.20 Does the media refer more to EDIT or KURA? In the previous week, Kura Oncology had 2 more articles in the media than Editas Medicine. MarketBeat recorded 15 mentions for Kura Oncology and 13 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.75 beat Kura Oncology's score of 0.72 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, EDIT or KURA? Editas Medicine has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Does the MarketBeat Community believe in EDIT or KURA? Kura Oncology received 122 more outperform votes than Editas Medicine when rated by MarketBeat users. Likewise, 69.75% of users gave Kura Oncology an outperform vote while only 53.47% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformEditas MedicineOutperform Votes31653.47% Underperform Votes27546.53% Kura OncologyOutperform Votes43869.75% Underperform Votes19030.25% Is EDIT or KURA more profitable? Kura Oncology has a net margin of 0.00% compared to Editas Medicine's net margin of -340.96%. Kura Oncology's return on equity of -44.09% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Editas Medicine-340.96% -80.13% -50.99% Kura Oncology N/A -44.09%-39.57% Do analysts rate EDIT or KURA? Editas Medicine presently has a consensus price target of $6.54, indicating a potential upside of 303.61%. Kura Oncology has a consensus price target of $25.50, indicating a potential upside of 292.91%. Given Editas Medicine's higher probable upside, equities research analysts plainly believe Editas Medicine is more favorable than Kura Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 2 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.31Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.92 SummaryKura Oncology beats Editas Medicine on 13 of the 18 factors compared between the two stocks. Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDIT vs. The Competition Export to ExcelMetricEditas MedicineBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$135.61M$2.95B$5.47B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.6330.0722.5118.54Price / Sales4.20494.82397.62103.35Price / CashN/A168.6838.1834.62Price / Book0.383.176.734.25Net Income-$153.22M-$72.35M$3.22B$248.18M7 Day Performance0.62%0.95%1.58%1.25%1 Month Performance43.36%8.28%4.05%3.76%1 Year Performance-70.38%-22.65%15.75%5.28% Editas Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDITEditas Medicine4.1591 of 5 stars$1.62-1.8%$6.54+303.6%-70.4%$135.61M$32.31M-0.63230Upcoming EarningsAnalyst UpgradeAnalyst RevisionNews CoverageKURAKura Oncology4.1265 of 5 stars$6.49-0.4%$25.50+293.2%-68.0%$523.85M$53.88M-2.75130Analyst ForecastNews CoveragePositive NewsZYBTZhengye BiotechnologyN/A$11.00-22.3%N/AN/A$518.83M$189.75M0.00278High Trading VolumeURGNUroGen Pharma4.2958 of 5 stars$11.06-1.8%$32.86+197.2%-20.8%$510.12M$90.40M-3.51200Analyst ForecastAnalyst RevisionNews CoverageSTOKStoke Therapeutics3.5108 of 5 stars$9.29-1.9%$24.67+165.5%-14.6%$507.48M$36.56M-4.43100Upcoming EarningsPositive NewsVERVVerve Therapeutics3.73 of 5 stars$5.56-3.0%$25.75+363.1%-8.3%$494.77M$32.33M-2.27110UPBUpstream BioN/A$9.06+3.2%$56.50+523.6%N/A$486.64M$2.37M0.0038News CoveragePositive NewsMNMDMind Medicine (MindMed)2.3304 of 5 stars$6.41+0.7%$25.11+292.1%-30.1%$482.73MN/A-2.8340Upcoming EarningsGHRSGH Research1.9531 of 5 stars$9.13-2.9%$30.86+238.2%-9.9%$474.76MN/A-11.5510News CoveragePositive NewsSAGESage Therapeutics3.7262 of 5 stars$7.67-1.2%$8.81+14.9%-43.7%$471.87M$41.24M-1.16690Earnings ReportAnalyst RevisionNews CoverageRGNXREGENXBIO4.4754 of 5 stars$9.41+3.0%$31.63+236.3%-39.3%$469.35M$83.33M-1.86370Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Kura Oncology Competitors Zhengye Biotechnology Competitors UroGen Pharma Competitors Stoke Therapeutics Competitors Verve Therapeutics Competitors Upstream Bio Competitors Mind Medicine (MindMed) Competitors GH Research Competitors Sage Therapeutics Competitors REGENXBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDIT) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EDIT Stock Free EDIT Stock Alerts